Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 14/20 | 0.71 |
| ▸ | EGFR | P00533 | 12/20 | 0.71 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.70 |
| ▸ | ABL1 | P00519 | 2/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.61 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.61 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.61 |
| ▸ | CSK | P41240 | 1/20 | 0.61 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.61 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2283239 | 0.97 | DDR1 (0.74) | BRAFEGFRDDR1ABL1FGFR1 | |
| SCHEMBL14702344 | 0.92 | DDR1 (0.83) | BRAFEGFRDDR1ABL1MAP3K7 | |
| SCHEMBL17208616 | 0.91 | DDR1 (0.85) | BRAFEGFRDDR1ABL1MAP3K7 | |
| SCHEMBL17208714 | 0.90 | BRAF (0.76) | BRAFEGFR | |
| SCHEMBL17208712 | 0.89 | BRAF (0.67) | BRAFEGFRDDR1ABL1FGFR1 | |
| SCHEMBL17208649 | 0.87 | MAPK14 (0.67) | BRAFEGFRDDR1ABL1MAP3K7 | |
| SCHEMBL17208648 | 0.86 | EGFR (0.59) | BRAFEGFRDDR1ABL1MAP3K7 | |
| SCHEMBL17515255 | 0.85 | DDR1 (0.95) | BRAFEGFRDDR1ABL1MAP3K7 | |
| SCHEMBL2283236 | 0.84 | BRAF (0.64) | BRAFEGFRDDR1ABL1FGFR1 | |
| SCHEMBL2289051 | 0.83 | BRAF (0.77) | BRAFEGFRDDR1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9180127-B2 | Type II Raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| EP-2937345-A2 | Type II raf kinase inhibitors | Dana-Farber Cancer Institute, Inc. (US) | 2015-10-28 | — | — | EP | disclosed |